GKOSGlaukos Corporation
$156.45
$0.39
(0.25%)
EarningsJul 29
Mkt Cap$9.21B
Vol382,992.00
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?
Key PointsAlex R. Thurman generated ~$1.6 million in gross proceeds by selling 10,000 shares at $155 per share on July 9...
Nasdaq News: Markets
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?
GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.
Zacks
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026...
Business Wire
Can ISRG's 'Quintuple Aim' Strategy Continue to Justify Premium Pricing?
Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth.
Zacks
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the...
Business Wire
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.
Zacks
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today...
Business Wire
Insider Selling: Glaukos (NYSE:GKOS) COO Sells 19,573 Shares of Stock
Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 19,573 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the completion of the sale, the chief operating officer...
MarketBeat
Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock
Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 10,000 shares of Glaukos stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $140.00, for a total value of $1,400,000.00. Following the completion of the transaction, the chief financial...
MarketBeat
Leana Wen Sells 1,700 Shares of Glaukos (NYSE:GKOS) Stock
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Leana Wen sold 1,700 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.35, for a total transaction of $243,695.00. Following the sale, the director directly owned 19,739...
MarketBeat
<
1
2
...
>
